Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Eike Floettmann"'
Publikováno v:
Toxicology and Applied Pharmacology. 329:85-95
Naloxegol is an opioid antagonist which has been developed for the treatment of patients with opioid induced constipation. In the nonclinical safety program naloxegol was shown to have a very benign toxicity profile. In the rat, but not the mouse, 2-
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics
Opioid-induced constipation (OIC) is a common side effect of opioid pharmacotherapy for the management of pain because opioid agonists bind to µ-opioid receptors in the enteric nervous system (ENS). Naloxegol, a polyethylene glycol derivative of nal
Publikováno v:
Clinical Pharmacokinetics. 56:573-582
Naloxegol is a peripherally acting µ-opioid receptor antagonist approved for use as an orally administered tablet (therapeutic doses of 12.5 and 25 mg) for the treatment of opioid-induced constipation. Over a wide dose range (i.e. single supratherap
Autor:
Rowe, Martin, Eike Floettmann, J.
Publikováno v:
DNA Virus Replication.
Externí odkaz:
https://doi.org/10.1093/oso/9780199637133.003.0004
Autor:
Tim J.D. Smith, Alan Martin Birch, Andrew V. Turnbull, Huw B. Jones, Linda K. Buckett, Jan Eike Floettmann, Carina Hallberg, David Lees
Publikováno v:
Toxicologic Pathology. 41:941-950
Acyl-coenzyme A: cholesterol O-Acyltransferase (ACAT) and Acyl-coenzyme A: diacylglycerol O-acyltransferase (DGAT) enzymes play important roles in synthesizing neutral lipids, and inhibitors of these enzymes have been investigated as potential treatm
Autor:
Simon M. Poucher, John Myatt, Joanne Teague, Laraine Gregory, Eike Floettmann, Clare D. Hammond, Huw B. Jones
Publikováno v:
Toxicologic Pathology. 38:393-401
The preclinical efficacy and safety of GPi921, a glycogen phosphorylase inhibitor, was assessed following twenty-eight days of administration to Zucker Diabetic Fatty (ZDF) rats. The ZDF rat is an animal model of type 2 diabetes mellitus (TTDM) which
Autor:
Paul Brennan, Martin Rowe, Sinead Keating, Ceri Alan Fielding, Eike Floettmann, Stuart Prince
Publikováno v:
Journal of Virology. 77:5000-5007
Epstein-Barr virus (EBV) is a potent growth-transforming agent of human B cells. It has previously been shown that viral latent membrane protein 1 (LMP1) is essential for EBV-induced transformation of normal B cells and contributes to maintenance of
Autor:
Peter K. Djali, John Unitt, Michael R. H. White, Geraint J. C. Wilde, Luminita Paraoan, David G. Spiller, Eike Floettmann, Glyn Nelson, Elaine Sullivan, Mark Browne
Publikováno v:
Journal of Cell Science. 115:1137-1148
Proteins of the NF-kappaB transcription factor family normally reside in the cytoplasm of cells in a complex with IkappaB inhibitor proteins. Stimulation with TNFalpha leads to proteosomal degradation of the IkappaB proteins and nuclear translocation
Publikováno v:
Toxicologic pathology. 43(3)
Diacylglycerol O-acyltransferase 1 (DGAT1) plays an important role in synthesizing lipids, and inhibitors of DGAT1 have been investigated as potential treatments for diabetes and metabolic diseases. DGAT1 knockout (−/−) mice are resistant to obes
Publikováno v:
Journal of Biological Chemistry. 276:984-992
The latent membrane protein-1 (LMP1) of Epstein-Barr virus induces gene transcription, phenotypic changes, and oncogenic transformation. One cellular gene induced by LMP1 is that for intercellular adhesion molecule-1 (ICAM-1), which participates in a